Functional Precision Oncology With Validated Clinical Impact
First Ascent moves beyond the standard of care by combining direct ex vivo drug exposure of the patient’s own tumor cells and molecular profiling.
This approach tests the individual patient’s actual biology, not just population-wide predictions, helping to validate the drugs and combinations that are right for that patient’s unique cancer.
First Ascent moves beyond the standard of care by combining direct ex vivo drug exposure of the patient’s own tumor cells and molecular profiling.
This approach tests the individual patient’s actual biology, not just population-wide predictions, helping to validate the drugs and combinations that are right for that patient’s unique cancer.
We need direction in this section
In a prospective clinical study published in Nature Medicine:
[Graphics]
83% of patients
achieved an objective response relative to their previous therapy*
83% of patients achieved an objective response
when care decisions were guided by our insights vs 13% without
[Eyebrow] Reports in
~10 days
We aim to deliver patient-specific insights in 10 days, which is fast enough to be clinically actionable.
*n=6.
How Our Proprietary Functional Precision Oncology Platform Works
Functional Precision Oncology is the next generation of clinical decision support in oncology, and it goes beyond the standard of care by focusing on the individual rather than the population. xDRIVE, our innovative technology, does just that.
Our platform uniquely combines 3 powerful technologies for personalized treatment insights: ex vivo live-cell drug sensitivity testing, genomics, and an individualized machine-learning model.
Functional Ex Vivo Drug Validation
Our proprietary cell-enrichment technology isolates and expands tumor cells from a patient’s biopsy. Then, it tests them within a microenvironment derived from the patient’s unique tumor characteristics to see how they respond to more than 150 FDA-approved drugs and combinations.
Genomic Sequencing
We perform DNA and RNA sequencing to uncover underlying mutations and molecular characteristics.
AI-powered xDRIVE Platform
Our proprietary, individualized machine-learning model integrates functional drug validation data with DNA/RNA sequencing to pinpoint the most effective drugs and combinations for the patient’s unique cancer biology.
Our difference is in our drug validation data. No one else has the capability of conducting ex vivo live-cell drug sensitivity testing with so many drugs and combinations—or the ability to produce results so quickly.
Working With First Ascent Biomedical
-
Collect a liquid or solid, core or needle fresh biopsy sample
-
Test live cancer cells ex vivo against a panel of more than 150 FDA-approved therapies and combinations
-
Deliver patient-specific insights in as soon as 10 days, which is fast enough to be clinically actionable
The ranked report HCPs receive includes the drugs and combinations showing the strongest and weakest evidence of effectiveness for your patient’s specific cancer cells, along with supporting research.
Support and Resources
Connect with us to arrange a presentation on our xDRIVE platform. We are happy to work with an oncologist on a specific patient referral.
Explore the FAQs
Explore our open trials.
We are currently involved in 2 clinical studies NCT05857969 [LS1] and NCT06024603. You can follow our progress in real time through the Government’s Clinical Trials website to read about our initial ASC Clinical Results and Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling below.